TG Therapeutics (TGTX) to Release Earnings on Wednesday

TG Therapeutics (NASDAQ:TGTX) will likely be issuing its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of $0.09 per share and revenue of $100.67 million for the quarter.

TG Therapeutics Stock Down 0.2 %

TGTX stock opened at $30.88 on Monday. TG Therapeutics has a fifty-two week low of $12.90 and a fifty-two week high of $36.84. The stock has a market cap of $4.81 billion, a PE ratio of -308.77 and a beta of 2.26. The firm’s 50-day simple moving average is $31.07 and its 200 day simple moving average is $27.84. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27.

Analyst Ratings Changes

Several brokerages have recently weighed in on TGTX. The Goldman Sachs Group upped their price objective on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. TD Cowen initiated coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price target on shares of TG Therapeutics in a research report on Wednesday, January 15th. JPMorgan Chase & Co. increased their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, November 25th. Finally, StockNews.com lowered TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 31st. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $40.67.

Insider Buying and Selling

In other news, CFO Sean A. Power sold 10,021 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the sale, the chief financial officer now owns 660,611 shares of the company’s stock, valued at $18,847,231.83. This represents a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.50% of the stock is owned by insiders.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.